# US 2025/0049966 A1 · Small molecule tracer for imaging alpha-synuclein aggregates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049966 A1
- Document ID: US20250049966A1
- Status: Published application
- Kind: A1
- Application number: 18/718,239
- Filed: 2022-12-12
- Published: 2025-02-13
- Earliest claimed: 2021-12-13
- Assignees: Fudan University
- Applicants: Fudan University
- Inventors: Yong CHU; Jian WANG; Jiang BIAN; Yiqi LIU; Xin LIN; Chenyang QIU; Jie HE; Deyong YE
- Web page: https://patentgrep.com/patent/US20250049966A1

## CPC

- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 31/423: condensed with carbocyclic rings
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C09K 11/06: containing organic luminescent materials
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C09K: MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE

## Abstract

The invention discloses a type of compound that can specifically bind to α-synuclein aggregates represented by Formula I, a radio-labelled compound thereof, a preparation method, and its use. The compound can be used as a tracer for optical imaging of α-synuclein aggregates in biological samples or in vivo (such as the brain). After radio-labelled, the compound of the invention can be used as a radio imaging tracer for PET, SPECT, and other imaging techniques to realize the detection of α-synuclein lesions by non-invasive visualization in vivo (such as the brain).

## Claims

### Claim 1

A compound represented by general Formula I, its pharmaceutically acceptable salt or solvate, which can be used as a tracer for the imaging diagnosis of α-synuclein accumulation diseases,
wherein,
Ring A is selected from benzene, pyridine, and pyrimidine;
R1 is selected from 4-6 membered nitrogen-containing cycloalkyl, amino group substituted with N, N-diC1-3 alkyl, C1-3 alkoxyl, nitro, halogen;
Ring B is selected from pyridine, piperazine, piperazinone;
R2 is selected from halogen, hydroxyl, C1-3 alkyl, C1-4 alkoxyl, and halogenated C1-4 alkoxyl;
wherein the halogen is selected from fluorine, bromine, or iodine.

### Claim 2 (depends on 1)

A compound, its pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R1 is preferably tetrahydropyrrole, N, N-dimethylamino, or methoxyl.

### Claim 3 (depends on 1)

A compound, its pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein one or more atoms of the compound of Formula I are the radioisotopes of that atom, of which preferably taken from 11C, 13N, 15O, 18F, 76Br, 123I, 125I, and 131I.

### Claim 4 (depends on 3)

A compound, its pharmaceutically acceptable salt or solvate thereof according to claim 3, wherein the compound represented by Formula I is selected from the following structures:
wherein one of the atoms marked with * is a radioisotope of that atom at least.

### Claim 5 (depends on 4)

A compound selected from the following structures, which is used as a precursor for the synthesis of the compound according to claim 4,
wherein, R3 is independently selected from hydroxyl, fluorine, bromine, iodine, nitro, borate group, TsO-(CH2)m—, MsO-(CH2)m—, wherein m is an integer from 0 to 4; R4 is independently selected from hydrogen, C1-3alkyl, and 4-6 membered nitrogen-containing cycloalkyl by cyclization of NR4R4, wherein one of the atoms marked with * is a radioisotope of that atom at least.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The use of a compound, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein a compound represented by Formula I or its pharmaceutically acceptable salt or solvate thereof can bind to α-synuclein aggregates and used as a tracer to image the diseases caused by α-synuclein accumulation.
